# IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Non-small-cell Lung Cancer (NSCLC)

> **NCT05118334** · PHASE1 · COMPLETED · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 30 (actual)

## Conditions studied

- NSCLC (Non-small-cell Lung Cancer)

## Interventions

- **DRUG:** Sintilimab
- **DRUG:** IBI310

## Key facts

- **NCT ID:** NCT05118334
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-12
- **Primary completion:** 2022-07-31
- **Final completion:** 2023-02-17
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2023-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05118334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05118334, "IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Non-small-cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05118334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*